Sarepta Therapeutics Inc »

  • Business » Sarepta Plunges on FDA Statement
    November 13, 2013, 07:21 GMT

    Biotechnology has been a hotspot for investors over the last year. Names including Gilead and Celgene have soared above the broad market returns as the street begun to realize the growth potential within the industry. However, not all biotechnology names are not created equal. Regulatory hurdles and competition within the space often causes great headache